Adverse Event Risk Up for >90 Days Versus >30 Days of Corticosteroids for Eczema
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 24, 2024 -- Use of oral corticosteroids for >90 days during one year is associated with a slightly increased risk of adverse events (AEs), according to a study published online July 19 in JAMA Network Open.
Yong Hyun Jang, M.D., Ph.D., from Kyungpook National University in Daegu, South Korea, and colleagues examined the association between long-term exposure to oral corticosteroids and occurrence of 11 AEs among adult patients with atopic dermatitis. Analysis included 164,809 cases and 328,303 controls.
The researchers found that 3.4 percent of cases and 3.2 percent of controls were exposed to oral corticosteroids for >30 days, while 0.4 percent in both groups were exposed to oral corticosteroids for >90 days. There was no increased risk of AEs with use of oral corticosteroids for >30 days (adjusted odds ratio, 1.00; 95 percent confidence interval, 0.97 to 1.04). However, the risk was higher with use of oral corticosteroids for >90 days (adjusted odds ratio, 1.11; 95 percent confidence interval, 1.01 to 1.23). For each cumulative or consecutive year of ever long-term use, there was a small elevation of risk for experiencing an AE.
"This study suggests that for patients with exacerbations of atopic dermatitis, limiting the duration of oral corticosteroid treatment to 90 days or less may limit adverse effects," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
WEDNESDAY, April 23, 2025 -- Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health...
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
FRIDAY, March 14, 2025 -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.